These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35409691)

  • 1. Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer.
    Bagaria J; Kim KO; Bagyinszky E; An SSA; Baek JH
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 3. Rectal cancer sub-clones respond differentially to neoadjuvant therapy.
    Frydrych LM; Ulintz P; Bankhead A; Sifuentes C; Greenson J; Maguire L; Irwin R; Fearon ER; Hardiman KM
    Neoplasia; 2019 Oct; 21(10):1051-1062. PubMed ID: 31521947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Lee IH; Kang K; Kang BW; Lee SJ; Bae WK; Hwang JE; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
    Med Oncol; 2018 Sep; 35(11):145. PubMed ID: 30206710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 7. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 8. The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
    Martinez-Useros J; Moreno I; Fernandez-Aceñero MJ; Rodriguez-Remirez M; Borrero-Palacios A; Cebrian A; Gomez Del Pulgar T; Del Puerto-Nevado L; Li W; Puime-Otin A; Perez N; Soengas MS; Garcia-Foncillas J
    BMC Cancer; 2018 Feb; 18(1):144. PubMed ID: 29409457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
    Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy and safety of total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in the treatment of locally advanced rectal cancer: a meta-analysis].
    Zhang YQ; Sun KG; Lu JY; Ma J; Yao N; Qin ZH; Yao YH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jun; 25(6):531-538. PubMed ID: 35754218
    [No Abstract]   [Full Text] [Related]  

  • 11. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
    Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
    Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
    Chen CJ; Yang CK; Jian JL; Guan S; Xie MM
    Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788
    [No Abstract]   [Full Text] [Related]  

  • 13. MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer.
    Du B; Wang X; Wu D; Wang T; Yang X; Wang J; Shi X; Chen L; Zhang W
    Mol Med Rep; 2018 Aug; 18(2):1909-1916. PubMed ID: 29956755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
    Greenbaum A; Martin DR; Bocklage T; Lee JH; Ness SA; Rajput A
    Clin Colorectal Cancer; 2019 Jun; 18(2):102-109. PubMed ID: 30935775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy.
    Ji D; Yi H; Zhang D; Zhan T; Li Z; Li M; Jia J; Qiao M; Xia J; Zhai Z; Song C; Gu J
    Cancer Immunol Res; 2018 Nov; 6(11):1401-1416. PubMed ID: 30282671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Genetic variations in MLH3 and MSH2 genes are associated with the sensitivity and prognosis in locally advanced rectal cancer patients receiving preoperative chemoradiotherapy].
    Yang J; Wang X; Zou SM; Li HM; Xiao Q; Feng YR; Huang Y; Feng T; Chen JN; Lin DX; Li YX; Jin J; Tan W
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):433-440. PubMed ID: 29936769
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
    Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
    Li D; Wu H; Feng R; Zhong D; Luo Y; Xiao Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Jun; 19(6):690-4. PubMed ID: 27353106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 20. [Identification of gene biomarkers to predict responses to neoadjuvant chemoradiotherapy in patients with rectal cancer and pathways enrichment analysis].
    Wang XJ; Yu Q; Chi P; Lin HM; Lu XR; Huang Y; Xu ZB; Huang SH; Sun YW; Ye DX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1183-1187. PubMed ID: 31874536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.